Martin Holst Lange, Executive vice president, head of Development

Dr Lange joined Novo Nordisk in 2002, working with growth hormone, GLP-2 and oral anti-diabetics as first operationally and subsequently medically responsible for several projects within Global Development.

Dr Lange worked two years in Novo Nordisk Inc., USA, from 2006-2008 in the Medical Department as Senior Medical Director. In 2008, Dr Lange moved back to Denmark as Vice President, Medical & Science liraglutide during the submission and approval phase, transferring in 2010 upon US approval of Victoza® to insulin degludec in a similar position.

From 2013 to 2017, he served as Corporate Project Vice President for Insulin & Diabetes Outcomes and subsequently Insulin & Devices, being responsible for the development and approval of the Novo Nordisk insulin portfolio. In January 2018, he was appointed Senior Vice President for Global Development, assuming the overall clinical development responsibilities of the Novo Nordisk pipeline. In March 2021, Dr Lange was appointed Executive Vice President Development, Novo Nordisk A/S. 

1997-2002: Dr Lange did clinical work as well as clinical research of which the latter, three years at the Department of Endocrinology, National University Hospital, Denmark. Dr Lange has served on the Board of Directors of Betabionics Inc., USA.

  • 2004: PhD in Endocrinology
  • 1997: Graduating as an MD, University of Copenhagen

Dr Lange is a Danish national, born October 1970.